Core Viewpoint - Autonomix Medical, Inc. is set to present its innovative catheter-based technology and initial findings from a clinical trial focused on treating pain in pancreatic cancer patients at the upcoming CRT Annual Meeting in March 2025 [1][2]. Company Overview - Autonomix is a medical device company dedicated to advancing technologies for diagnosing and treating diseases related to the nervous system [3]. - The company's platform technology features a catheter-based microchip sensing array that can detect and differentiate neural signals with approximately 3,000 times greater sensitivity than existing technologies [3]. - The initial focus of this technology is on pain management, particularly for pancreatic cancer, which is known for causing severe pain and lacks effective treatment options [4]. Clinical Presentation Details - The presentation titled "Catheter-Based Transvascular RF Neural Ablation For Severe Pancreatic Cancer Pain: First Results From The Elpis Study" will be delivered by Dr. Robert Schwartz, Chief Medical Officer of Autonomix [2]. - The session is scheduled for March 10, 2025, from 2:00 PM to 2:40 PM ET during the Innovation HUB session at the CRT Annual Meeting [2]. Technology Potential - The technology has the potential to revolutionize the treatment of various conditions involving the peripheral nervous system, with applications extending beyond pancreatic cancer to areas such as cardiology, hypertension, and chronic pain management [4].
Autonomix Medical, Inc. Selected for Podium Presentation at the 2025 CRT Annual Meeting